- Patients with episodic migraine who received subcutaneous fremanezumab needed acute headache and migraine-specific medication less often than those who received a placebo and reported lower incidences of nausea or vomiting, photophobia, and phonophobia.
Why this matters
- These findings were observed with both a monthly and quarterly dose regimen.
- The phase 3 (HALO) randomized, double-blind, placebo-controlled trial enrolled patients with episodic migraine.
- Patients received subcutaneous fremanezumab (225 mg monthly, n=290; 675 mg quarterly, n=291) or placebo (n=294) for 12 weeks.
- Funding: Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel.
- Treatment with fremanezumab (monthly and quarterly, respectively) vs placebo reduced:
- number of days of acute headache medication use (least-squares mean [LSM] change, −1.4 and −1.3; Pboth<.001 and>
- migraine-specific acute headache medication use (LSM change, −2.2 and −2.2; Pboth<.001>
- number of days with nausea/vomiting (difference: −0.7 [P<.001 and>
- photophobia (difference: −0.9 [P<.001 and>
- phonophobia (difference: −1.0 [P<.001 and>
- Prespecified exploratory analyses.
Coauthored with Chitra Ravi, MPharm